BBNX · Beta Bionics, Inc.

Track BBNX — free

$17.57 -0.51 (-2.82%) At close · Aug 14

Market Cap

$790.47M

44.99M

Up next

Next earnings call

Nov 1, 2026 Est · unconfirmed · in 11 wks

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed Jul 29, 2026

AI Brief

TL;DR.

Bullish

Bearish

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Ask ALVIS about this →

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Buy Momentum Strong Sentiment Neutral Fundamentals Excellent Quant / Vol Very High

Market backdrop VIX 14.3 · calm Equity put/call 0.52

Technical

price trend

Buy

50 / 200-day cross No cross

Price vs 200-day avg +2%

above

Price vs 50-day avg +13%

above

RSI (14) 60

neutral

MACD trend Positive

52-week position 38%

mid-range

Momentum

relative strength

Strong

1-month return +2%

trailing

6-month return +28%

trailing

YTD return −42%

this year

Relative strength +14%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $16 › 200d $17 — 200d above 50d

Institutional flow Accumulating

+4% holders QoQ · +31 funds added

Insider flow Distributing

Net -$472.5K over 90 days · 100% sells

Short interest Rising

16.90% of float · ▲ +15.1% MoM · 6.0 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

137 holders — mid 1-yr range

Squeeze score 76

high risk · 0–100

Fundamentals

Excellent

Revenue growth +54%

Y/Y

Gross margin 55%

expanding

EPS growth +79%

Y/Y

Free cash flow $-56.2M

Balance sheet $31.6M

net cash

Quant / Vol

risk profile

Very High

Volatility 83%

annualized · 1-yr

Max drawdown −72%

past year

ATR 6.8%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Latest guidance · from the 8-K filed Jul 29, 2026

Total revenue · full year 2026 $131M – $136M

Gross margin · full year 2026 58.5% – 59.5%

New patient starts reimbursed through the PBP channel · full year 2026 37% – 39%

Prior guidance period ended · from the 8-K filed Jan 8, 2026

Net sales · fourth quarter 2025 at least $32M

Durable Medical Equipment (DME) channel net sales · fourth quarter 2025 at least $22.3M

Pharmacy Benefit Plan (PBP) channel net sales · fourth quarter 2025 at least $9.7M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy

0 · 3 · 3

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+2% Bullish

Price vs 50-day avg

+13% Bullish

RSI (14)

60 Neutral

MACD trend

Positive Bullish

52-week position

38% Neutral

Market signals — smart money & positioning

Bearish · 2 of 6

Trend (MA cross) No cross

50d $16 › 200d $17 — 200d above 50d

Institutional flow Accumulating

+4% holders QoQ · +31 funds added

Insider flow Distributing

Net -$472.5K over 90 days · 100% sells

Short interest Rising

16.90% of float · ▲ +15.1% MoM · 6.0 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

137 holders — mid 1-yr range

Price context

position in its 52-week range

Range low $9 Now $18 · 38% Range high $32

vs 200-day avg +2% vs 50-day avg +13%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
New patient starts from multiple daily injections (MDI)	69%	the second quarter	—

Installed customer base	35,011	Q4 FY2025	—
New patient starts	19,713	FY2025	—
New patient starts from MDI as a percentage of total new patient starts	70%	FY2025	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Devices — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
BBNX Beta Bionics, Inc. this stock	$790.47M	-42.3%	+53.9%	—	16.9%
ABT Abbott Laboratories	$193.78B	-11.2%	+5.7%	31.2	1.3%
SYK Stryker Corp	$130.11B	-3.5%	+11.2%	35.2	2.2%
MDT Medtronic plc	$116.83B	-5.0%	+8.4%	24.5	1.4%
BSX Boston Scientific Corp	$75.11B	-45.6%	+12.5%	21.0	1.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

137

% held: 106.9%
Net QoQ: -1.3M sh
Top holder: EVENTIDE ASSET MANAGEMENT…

Held Float

View

Held by Funds

Fund positions

126

View

Short & Settlement

Short Interest Rising

Shares short

7.6M

Days to cover: 6.0d
Change: +995.2K sh

View

Short Volume

Short vol %

43%

As of: Aug 14, 2026

Short Total

View

Fails to Deliver

FTD shares

2.8K

Value: $46.9K
As of: Jul 7, 2026

View

Off-Exchange

Off-exchange %

40.9%

Week of: Jul 6, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$472.5K

Buyers / Sellers: 0 / 5

Buyers Sellers

View

Financials

Revenue (FY)

$100.3M

Net income (FY): $-73.2M
EPS diluted: $-1.81

View

Filings

SEC Filings

Latest

8-K

Filed: Jul 29, 2026
This year: 11

View

Proposed Sales

Value

$19.2K

Shares: 1.4K
Filed: Jun 24, 2026

View

Exempt Offerings

Offering

$101.8M

Filed: Sep 15, 2023

View

Earnings & Events

Earnings Calls

Last call

Jul 29, 2026

View

Performance

	5D	20D	120D	MTD	YTD
BBNX	+10.5%	+1.6%	+27.7%	+36.9%	-42.3%
SPY	+0.4%	+4.5%	+13.8%	+3.9%	+13.9%
vs SPY	+10.1%	-2.8%	+13.9%	+33.0%	-56.2%

Key facts CIK 1674632 CUSIP 08659B102 13F (30d) 130 filings 128 filers Visit website Investor relations

BBNX · Beta Bionics, Inc.

Price & Indicators

Up next

AI Brief

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance